PhenomeX stands behind its ground-breaking
Beacon® technology that advances human health globally; remains
confident it will prove its case in court
EMERYVILLE, Calif., Aug. 7, 2023
/PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell
biology company, today announced that the series of lawsuits
filed by AbCellera in 2020 will now proceed in
litigation. AbCellera contends that PhenomeX's Beacon®
platform infringes certain U.S. patents claiming methods of cell
culture and analysis developed on microfluidic chips featuring
microwells and pressurized valves—neither of which are found in
PhenomeX's OptoSelect® chips. PhenomeX's Beacon platform is
protected by a growing portfolio of over 500 patents and has been
featured in a number of groundbreaking studies, including a
study on SARS-CoV-2 research recently published in Cell
Reports about the Omicron variant. PhenomeX is
confident it will prevail in this litigation and continue its
mission to develop and deliver critical cell biology research
solutions to its customers.
"We are confident that we will demonstrate in court the
uniqueness of our patented technology and the value it brings to
functional cell biology research and the advancement of human
health," said Dr. Siddhartha Kadia, chief executive officer of
PhenomeX. "We believe that AbCellera's claims are without merit and
remain steadfast in our commitment to advancing functional cell
biology through our innovative and proven technology."
The Beacon platform's features are unique amongst single-cell
screening technologies. The Beacon system allows
multi-parameter, selective movement of single cells into
nanoliter-sized NanoPen® chambers for further analysis, loading
single-cells into more than 70% of the NanoPen chambers on the
chip, up to 12-16 assays to be run on the same set of cells in a
single day, and selective export of live cells. No other
microfluidic platform on the market approaches these
capabilities.
The litigation has resumed, as expected, following resolution of
an administrative proceeding on the validity of AbCellera's U.S.
Patent No. 10,087,408 over certain earlier patents and
publications. That administrative proceeding is now on
appeal.
About PhenomeX Inc.
PhenomeX is empowering scientists to leverage the full potential
of each cell and drive the next era of functional
cell biology that will advance human health. We enable
scientists to reveal the most complete insights on cell function
and obtain a full view of the behavior of each cell. Our unique
suite of proven high-throughput tools and services offer
unparalleled resolution and speed, accelerating the insights that
are key to advancing discoveries that can profoundly improve the
prevention and treatment of disease. Our award-winning
platforms are used by researchers across the globe, including those
at the top 15 global pharmaceutical companies and approximately 85%
of leading U.S. comprehensive cancer centers.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding PhenomeX or its
products, they are forward-looking statements reflecting the
current beliefs and expectations of management. Such
forward-looking statements involve substantial known and unknown
risks and uncertainties that relate to future events, and actual
results and product performance could differ significantly from
those expressed or implied by the forward-looking statements.
PhenomeX undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties relating to the Company's growth and continual
evolution see the statements in the "Risk Factors" sections, and
elsewhere, in our filings with the U.S. Securities and Exchange
Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phenomex-announces-lifting-of-the-stay-in-abcellera-patent-infringement-case-301894517.html
SOURCE PhenomeX